Ketamine for Chronic Sickle Cell Pain

 

Ketamine for Chronic Sickle Cell Pain Summary

Research into Ketamine for pain management shows it to be a safe alternative to opioids in emergency settings. A 2025 study has shown that 20-46% of patients achieved clinically meaningful improvements in pain management and found the benefits were sustained 6 months post treatment. A 2025 study found Ketamine to match the effect of opioids for immediate pain relief without the side effects. Overall the studies show that Ketamine is an effective tool for treating pain.

Sickle cell disease (SCD) is an inherited blood disorder that affects approximately 100,000 people in United States. Sickle Cell Disease turns healthy blood cells from being round shaped to sickle shaped, hard and sticky. These cells die quicker than normal cells, causing a shortage of red blood cells and causing mild to severe chronic pain. This disease is caused by a mutation in the gene that provides instructions to the body to make hemoglobin, a major part of the disease is the chronic severe pain.

Sickle cell anemia causes patients such severe pain that they can end up at the hospital for treatment. To manage this disease most patients rely on opioids and IV hydration. For those who can't take opioids or have a pre-existing condition, ketamine therapy has proven to be an effective way to deal with pain management.

Note: Ketamine is FDA approved for general use in anesthesia and as of August 2025 it is approved for surgical pain management in perioperative settings.

1) Mechanism of Action

Ketamine is used as an analgesic, especially for severe acute pain and selected chronic pain syndromes.

  • NMDA receptor antagonism causes a reduction in glutamate-mediated pain transmission
  • Decreases central sensitization
  • Reverses opioid tolerances
  • Inhibits the wind-up phenomenon (progressive amplification of pain signals)
  • Enhances descending inhibitory pain pathways

These effects are especially relevant in neuropathic pain and opioid-resistant pain.

2) Clinical Indications

  • Chronic Sickle Cell pain with opioid dependence or tolerance
  • Refractory pain
  • Opioid-tolerant or opioid-resistant pain

Ketamine is often used as an adjunct rather than a first-line analgesic.

3) Clinical Effects

  • Rapid analgesia
  • Improved pain control in opioid-resistant cases
  • Reduction in pain intensity
  • Reduction in hyperalgesia and allodynia
  • Improved control of baseline chronic pain

In chronic pain, ketamine may sometimes provide relief that lasts beyond the infusion period by helping reset abnormal pain processing and can last for days and even weeks after the ketamine session.

4) Potential Advantages

  • Effective in opioid-resistant pain
  • Opioid-sparing, which may reduce opioid adverse effects and opioid dose requirements
  • Minimal respiratory depression
  • Useful in some hemodynamically unstable patients
  • Treats both the pain and depression

These features make ketamine valuable in emergency, perioperative, and selected chronic pain settings.

5) Limitations and Risks

  • Variable response in chronic pain patients
  • Short duration of benefit in some cases
  • Need for monitoring at higher doses
  • Potential for misuse or dependence

6) Adverse Effects

  • Dissociation
  • Hallucinations or perceptual disturbances
  • Dizziness
  • Nausea/vomiting
  • Sedation
  • Increased blood pressure and heart rate

With repeated or long-term use

  • Cystitis (ketamine bladder syndrome)
  • Cognitive effects
  • Potential hepatotoxicity

7) Current Clinical Role

  • Used in SCD pain management
  • Reserved for refractory chronic pain
  • Typically used as an adjunct to other analgesics